Global Cerebral Angiography Market Overview:
Cerebral Angiography also called intra-arterial digital subtraction angiography is used to detect abnormalities like Arteriovenous, Malformations and aneurysms from the images of blood vessels around the brain. These abnormalities may lead to bleeding in the brain or a stroke. To perform this test, a contrast medium is injected into the blood and the catheter is inserted into the artery which helps the x-ray to create a clearer picture. This procedure takes usually from one to three hours.
Growth Drivers
- Increasing Prevalence of Coronary Diseases
- Increasing Demand of Minimally Invasive Surgeries
Roadblocks
- High Costs Associated with the Cerebral Angiography
- Potential Risk during the Procedure like Damage to Blood Vessel, Blood Clots around Catheter Tips
Opportunities
- Government Initiatives to Improve Health Care Infrastructure in Developing Countries
Challenges
- Fluctuating Upgradation of Angiography Devices
- Lack of Awareness among the People
Competitive Landscape:
Cerebral Angiography has various players in the market and is focusing on continuous research and development in cerebral angiography technological advancement. They are also increasing investment for the same, and planning on strategic activities like mergers, partnerships, and collaborations. This will helps them expand and maintain their competencies edge and serve better to patients.
Some of the key players profiled in the report are GE Healthcare (United States), Siemens Healthineers (Germany), Samsung Medison (South Korea), St. Jude Medical Inc. (United States), Abbott Laboratories (United States), Shimadzu Corporation (Japan), Hitachi Medical Corporation (Japan), Bayer Ag (Germany), Allengers (India) and OSCOR Inc. (United States). Additionally, following companies can also be profiled that are part of our coverage like Degania Silicone Ltd. (Israel), CathRx Ltd. (Australia), Toshiba Medical Systems Corporation (Japan), Hitachi Medical Corporation (Japan), TERUMO Corporation (Japan) and Koninklijke Philips N.V. (Netherlands). Analyst at AMA Research see United States Players to retain maximum share of Global Cerebral Angiography market by 2026. Considering Market by Gender, the sub-segment i.e. Male will boost the Cerebral Angiography market.
Latest Market Insights:
On 9th January 2018, Hitachi Healthcare Americas Corporation, a wholly-owned subsidiary of Hitachi, Ltd. and a leading provider of medical imaging modalities to hospital and ambulatory clients nationwide, announced that it has entered into an agreement to acquire VidiStar, LLC, a Greenville, SC-based company focused on reinventing how doctors review and report on diagnostic exams to drive productivity, portability, and improved communication and clinical decision making.
On 28th February 2019, schema view, the worldwide leader in advanced imaging for stroke care and research, announced RAPID ANGIO, a complete neuroimaging solution for the angiography suite that integrates iSchemaView’s RAPID software with syngo DynaCT Multiphase from Siemens Healthineers.
What Can be Explored with the Cerebral Angiography Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Cerebral Angiography Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Cerebral Angiography
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Cerebral Angiography market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Cerebral Angiography market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers, Raw Material Suppliers, Distributors and Traders, Research Organisations, Government Agencies and Organizations.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.